Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Investigating Lower Dose Stereotactic Radiosurgery for Brain Metastases

Recruiting
18 years - 100 years
All
42 participants needed
1 Location

Brief description of study.

The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.

Detailed description of study

Researchers will collect a blood sample and information from participants' medical record. Participants will receive stereotactic radiosurgery (SRS) to a dose according to the size of their metastatic brain disease. Participants will undergo normal clinical (examinations) and radiographic (brain MRI with contrast) follow-up one month after SRS and every three months after SRS for a full year.

None of the procedures participants undergo will be experimental; all are standard of care. However, the lower dose of stereotactic radiosurgery they will receive is not standard of care.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Metastases,brain tumor,metastasis,tumor
  • Age: 18 years - 100 years
  • Gender: All

Individuals at least 18 years of age with 1-10 solid tumor brain metastases.

Individuals with an existing autoimmune disease will not be eligible.

Updated on 19 Feb 2024. Study ID: 1906336263

This study investigates the effects of using a lower dose of stereotactic radiosurgery, such as Gamma Knife or Linear Accelerator, for patients with brain metastases who are also receiving immunotherapy. Brain metastases occur when cancer cells spread from their original site to the brain. The study aims to understand if a lower dose can be effective and safe.

Participants will have a blood sample taken and information collected from their medical records. They will receive stereotactic radiosurgery tailored to the size of their brain tumors. Follow-up includes regular clinical exams and brain MRIs with contrast, starting one month after treatment and continuing every three months for one year.

  • Who can participate: Adults aged 18 years and older with 1 to 10 solid tumor brain metastases can participate. Those with existing autoimmune diseases are not eligible.
  • Study details: Participants will undergo standard care procedures, including blood sampling and medical record review. They will receive a lower dose of stereotactic radiosurgery, which is not standard care.
  • Study Timelines: The study will last one year.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here